Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05670951
PHASE3
Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
Sponsor: Elgan Pharma Ltd.
View on ClinicalTrials.gov
Summary
The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.
Official title: A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
Key Details
Gender
All
Age Range
1 Day - 5 Days
Study Type
INTERVENTIONAL
Enrollment
360
Start Date
2025-02-27
Completion Date
2029-05
Last Updated
2026-01-23
Healthy Volunteers
No
Conditions
Interventions
DRUG
ELGN-2112
Human insulin \[rDNA\]
DRUG
Placebo
Placebo
Locations (1)
Laniado Hospital
Netanya, Israel